 <h1>Fragmin Side Effects</h1><p class="drug-subtitle"><b>Generic Name:</b> <i>dalteparin</i></p><ul class="ddc-anchor-links"><li>Consumer</li>
<li>Professional</li></ul><p class="ddc-notification"><b>Note:</b> This document contains side effect information about dalteparin. Some of the dosage forms listed on this page <em>may not</em> apply to the brand name Fragmin.</p><h2>In Summary</h2><p><b>Common side effects of Fragmin include:</b> pain at injection site. <b>Other side effects include:</b> hematoma at injection site and increased serum alanine aminotransferase.  See below for a comprehensive list of adverse effects.</p><h2 class="ddc-anchor-offset" id="consumer">For the Consumer</h2><p><i>Applies to dalteparin: subcutaneous solution</i></p><h3>Warning</h3><p class="blackboxWarning-title">Subcutaneous route (Solution)</p><p>Patients anticoagulated with low molecular weight heparins or heparinoids who receive neuraxial anesthesia or undergo a spinal puncture are at risk for epidural or spinal hematomas, which may result in long-term or permanent paralysis. The use of indwelling epidural catheters, concomitant drugs that also affect hemostasis (eg, NSAIDs, platelet inhibitors, or other anticoagulants), history of traumatic or repeated epidural or spinal punctures, or history of spinal deformity or spinal surgery further increase this risk. The optimal timing of dalteparin administration and a neuraxial procedure is unknown. Frequent monitoring for signs and symptoms of neurological impairment is recommended. Seek urgent treatment if neurological compromise occurs.</p><h3>Side effects requiring immediate medical attention</h3><p>Along with its needed effects, dalteparin (the active ingredient contained in Fragmin) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.</p><p>
<b>Check with your doctor immediately</b> if any of the following side effects occur while taking dalteparin:</p><p>
<i>More common</i>
</p><ul>
<li>Bruise</li>
<li>deep, dark purple bruise, pain, or swelling at the injection site</li>
<li>nosebleed</li>
</ul><p>
<i>Less common</i>
</p><ul>
<li>Bleeding of the gums</li>
<li>constipation</li>
<li>coughing up blood</li>
<li>difficulty with breathing or swallowing</li>
<li>dizziness</li>
<li>headache</li>
<li>increased menstrual flow or vaginal bleeding</li>
<li>paralysis</li>
<li>prolonged bleeding from cuts</li>
<li>red or black, tarry stools</li>
<li>red or dark brown urine</li>
<li>severe stomach pain</li>
<li>unexplained pain, swelling, or discomfort, especially in the chest, abdomen or stomach, joints, or muscles</li>
<li>unusual bleeding or bruising</li>
<li>vomiting of blood or material that looks like coffee grounds</li>
<li>weakness</li>
</ul><p>
<i>Rare</i>
</p><ul>
<li>Back pain</li>
<li>bleeding from mucous membranes</li>
<li>bluish or black discoloration, flushing, or redness of the skin</li>
<li>burning, pricking, tickling, or tingling sensation</li>
<li>cough</li>
<li>feeling faint</li>
<li>fever</li>
<li>leg weakness</li>
<li>numbness</li>
<li>problems with bowel or bladder function</li>
<li>skin rash (which may consist of pinpoint, purple-red spots), hives, or itching</li>
<li>sloughing of the skin at the injection site</li>
<li>swelling of the eyelids, face, or lips</li>
<li>tightness in the chest</li>
</ul><p>
<i>Incidence not known</i>
</p><ul>
<li>Blue-green to black skin discoloration</li>
<li>decrease in height</li>
<li>pain in the ribs, arms, or legs</li>
</ul><h3>Side effects not requiring immediate medical attention</h3><p>Some side effects of dalteparin may occur that usually <b>do not need medical attention</b>. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.</p><p>Check with your health care professional if any of the following side effects <b>continue or are bothersome</b> or if you have any questions about them:</p><p>
<i>Incidence not known</i>
</p><ul>
<li>Hair loss or thinning of hair</li>
</ul><p>
<!-- end subcutaneous solution --><div class="related-links"><svg aria-hidden="true" class="ddc-icon ddc-icon-info" focusable="false" height="22" viewbox="0 0 24 24" width="22" xmlns="http://www.w3.org/2000/svg"><path d="M14 2H6c-1.1 0-1.99.9-1.99 2L4 20c0 1.1.89 2 1.99 2H18c1.1 0 2-.9 2-2V8l-6-6zm2 16H8v-2h8v2zm0-4H8v-2h8v2zm-3-5V3.5L18.5 9H13z"></path></svg> <span>Managing side effects <span class="ddc-text-nowrap">(general information)</span></span></div>
<h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to dalteparin: subcutaneous solution</i></p><h3>General</h3><p>The most common side effects were any bleeding, postoperative transfusion, transaminase increases, and injection site pain.<sup>[Ref]</sup></p><h3>Cardiovascular</h3><p><b>Very common</b> (10% or more): Any bleeding (up to 18.5%)</p>
<p><b>Common</b> (1% to 10%): Major bleeding reactions</p>
<p><b>Postmarketing reports</b>: Prosthetic cardiac valve thrombosis<sup>[Ref]</sup></p><p>A bleeding reaction was considered major if accompanied by a decrease in hemoglobin of 2 g/dL or greater in connection with clinical symptoms, a transfusion was required, bleeding led to interruption of treatment or death, bleeding caused a significant clinical event, bleeding resulted in reoperation, or retroperitoneal or intracranial bleeding occurred.<sup>[Ref]</sup></p><h3>Other</h3><p><b>Very common</b> (10% or more): Postoperative transfusion (up to 15.9%)</p>
<p><b>Common</b> (1% to 10%): Wound hematoma, reoperation due to bleeding<sup>[Ref]</sup></p><h3>Hepatic</h3><p><b>Very common</b> (10% or more): Grades 2 through 4 increases in AST and ALT (up to 14%)</p>
<p><b>Common</b> (1% to 10%): Asymptomatic increases in transaminase levels (serum glutamic oxaloacetic transaminase/AST and Serum glutamic pyruvic transaminase/ALT) greater than 3 times the upper limit of normal, grades 3 and 4 increases in AST and ALT<sup>[Ref]</sup></p><h3>Nervous system</h3><p><b>Postmarketing reports</b>: Epidural/spinal hematoma, intracranial bleed<sup>[Ref]</sup></p><h3>Local</h3><p><b>Very common</b> (10% or more): Injection site pain (up to 12%)</p>
<p><b>Common</b> (1% to 10%): Injection site hematoma<sup>[Ref]</sup></p><h3>Hematologic</h3><p><b>Common</b> (1% to 10%): Reversible non-immunologically-mediated thrombocytopenia (type I)</p>
<p><b>Rare</b> (less than 0.1%): Immunologically-mediated heparin-induced thrombocytopenia (type II, with or without associated thrombotic complications)<sup>[Ref]</sup></p><h3>Genitourinary</h3><p><b>Common</b> (1% to 10%): Hematuria<sup>[Ref]</sup></p><h3>Immunologic</h3><p><b>Uncommon</b> (0.1% to 1%): Allergic reaction</p>
<p><b>Rare</b> (less than 0.1%): Fever</p>
<p><b>Frequency not reported</b>: Anaphylactoid reaction<sup>[Ref]</sup></p><h3>Dermatologic</h3><p><b>Uncommon</b> (0.1% to 1%): Rash, urticaria, pruritus</p>
<p><b>Rare</b> (less than 0.1%): Bullous eruptions, skin necrosis, alopecia<sup>[Ref]</sup></p><h3>Hypersensitivity</h3><p><b>Uncommon</b> (0.1% to 1%): Hypersensitivity<sup>[Ref]</sup></p><h3>Metabolic</h3><p><b>Uncommon</b> (0.1% to 1%): Hyperkalemia<sup>[Ref]</sup></p><h3>Musculoskeletal</h3><p><b>Uncommon</b> (0.1% to 1%): Osteoporosis<sup>[Ref]</sup></p><h3>Endocrine</h3><p><b>Postmarketing reports</b>: Hypoaldosteronism<sup>[Ref]</sup></p><h3>Gastrointestinal</h3><p><b>Frequency not reported</b>: Gastrointestinal bleeding</p>
<p><b>Postmarketing reports</b>: Retroperitoneal bleed<sup>[Ref]</sup></p><h3>Renal</h3><p><b>Frequency not reported</b>: Serum creatinine increased<sup>[Ref]</sup></p><div class="referenceList"><h4 id="refs">References</h4><p id="ref_1">1. Cerner Multum,  Inc. "Australian Product Information." O 0</p><p id="ref_2">2. "Product Information. Fragmin (dalteparin)." Pharmacia and Upjohn, Kalamazoo, MI. </p><p id="ref_3">3. Cerner Multum,  Inc. "UK Summary of Product Characteristics." O 0</p></div>
<div class="more-resources" id="moreResources">
<h2>More about Fragmin (dalteparin)</h2>
<ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy or 
Breastfeeding</li>
<li>Dosage Information</li>
<li>Drug Interactions</li>
<li>Compare Alternatives</li>
<li>Pricing &amp; Coupons</li>
<li>En Espa√±ol</li>
<li>1 Review</li>
<li>Drug class: heparins</li>
</ul>
<h3>Consumer resources</h3>
<ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>Fragmin &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
</ul>
<h3>Professional resources</h3>
<ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li data-more-config-id="list-data-resources-professional">... +1 more</li>
</ul>
<h3>Related treatment guides</h3>
<ul class="more-resources-list more-resources-list-conditions">
<li>Deep Vein Thrombosis Prophylaxis after Hip Replacement Surgery</li>
<li>Angina</li>
<li>Deep Vein Thrombosis Prophylaxis after Abdominal Surgery</li>
<li>Deep Vein Thrombosis Prophylaxis after Orthopedic Surgery</li>
<li data-more-config-id="list-data-resources-conditions">... +3 more</li>
</ul>
</div>
<h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p>
<p>Some side effects may not be reported. You may report them to the FDA.</p>
<p class="ddc-disclaimer-link">Medical Disclaimer</p>
<script>
function showRefs(refs) {
	if (!document.querySelectorAll) {
		return;
	}

	var referenceIds = refs ? refs.split(',') : [];
	var referenceTitle = referenceIds.length
		 ? "References relevant to chosen section <span class='ddc-text-size-small font-weight-normal'>(<a href='#refs' onclick='showRefs(\"\"); return false;'>Show all references</a>)</span>"
		 : "References";
	document.getElementById('refs').innerHTML = referenceTitle;

	// Show/hide reference items
	var referenceList = document.querySelectorAll('.referenceList p');
	referenceList.forEach(function(item) {
		var id = item.id.replace('ref_', '');
		if (!referenceIds.length || referenceIds.includes(id)) {
			item.style.display = 'block';
		}
		else {
			item.style.display = 'none';
		}
	});
}
</script>
</p><h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to dalteparin: subcutaneous solution</i></p><h3>General</h3><p>The most common side effects were any bleeding, postoperative transfusion, transaminase increases, and injection site pain.<sup>[Ref]</sup></p><h3>Cardiovascular</h3><p><b>Very common</b> (10% or more): Any bleeding (up to 18.5%)</p><p><b>Common</b> (1% to 10%): Major bleeding reactions</p><p><b>Postmarketing reports</b>: Prosthetic cardiac valve thrombosis<sup>[Ref]</sup></p><p>A bleeding reaction was considered major if accompanied by a decrease in hemoglobin of 2 g/dL or greater in connection with clinical symptoms, a transfusion was required, bleeding led to interruption of treatment or death, bleeding caused a significant clinical event, bleeding resulted in reoperation, or retroperitoneal or intracranial bleeding occurred.<sup>[Ref]</sup></p><h3>Other</h3><p><b>Very common</b> (10% or more): Postoperative transfusion (up to 15.9%)</p><p><b>Common</b> (1% to 10%): Wound hematoma, reoperation due to bleeding<sup>[Ref]</sup></p><h3>Hepatic</h3><p><b>Very common</b> (10% or more): Grades 2 through 4 increases in AST and ALT (up to 14%)</p><p><b>Common</b> (1% to 10%): Asymptomatic increases in transaminase levels (serum glutamic oxaloacetic transaminase/AST and Serum glutamic pyruvic transaminase/ALT) greater than 3 times the upper limit of normal, grades 3 and 4 increases in AST and ALT<sup>[Ref]</sup></p><h3>Nervous system</h3><p><b>Postmarketing reports</b>: Epidural/spinal hematoma, intracranial bleed<sup>[Ref]</sup></p><h3>Local</h3><p><b>Very common</b> (10% or more): Injection site pain (up to 12%)</p><p><b>Common</b> (1% to 10%): Injection site hematoma<sup>[Ref]</sup></p><h3>Hematologic</h3><p><b>Common</b> (1% to 10%): Reversible non-immunologically-mediated thrombocytopenia (type I)</p><p><b>Rare</b> (less than 0.1%): Immunologically-mediated heparin-induced thrombocytopenia (type II, with or without associated thrombotic complications)<sup>[Ref]</sup></p><h3>Genitourinary</h3><p><b>Common</b> (1% to 10%): Hematuria<sup>[Ref]</sup></p><h3>Immunologic</h3><p><b>Uncommon</b> (0.1% to 1%): Allergic reaction</p><p><b>Rare</b> (less than 0.1%): Fever</p><p><b>Frequency not reported</b>: Anaphylactoid reaction<sup>[Ref]</sup></p><h3>Dermatologic</h3><p><b>Uncommon</b> (0.1% to 1%): Rash, urticaria, pruritus</p><p><b>Rare</b> (less than 0.1%): Bullous eruptions, skin necrosis, alopecia<sup>[Ref]</sup></p><h3>Hypersensitivity</h3><p><b>Uncommon</b> (0.1% to 1%): Hypersensitivity<sup>[Ref]</sup></p><h3>Metabolic</h3><p><b>Uncommon</b> (0.1% to 1%): Hyperkalemia<sup>[Ref]</sup></p><h3>Musculoskeletal</h3><p><b>Uncommon</b> (0.1% to 1%): Osteoporosis<sup>[Ref]</sup></p><h3>Endocrine</h3><p><b>Postmarketing reports</b>: Hypoaldosteronism<sup>[Ref]</sup></p><h3>Gastrointestinal</h3><p><b>Frequency not reported</b>: Gastrointestinal bleeding</p><p><b>Postmarketing reports</b>: Retroperitoneal bleed<sup>[Ref]</sup></p><h3>Renal</h3><p><b>Frequency not reported</b>: Serum creatinine increased<sup>[Ref]</sup></p><p id="ref_1">1. Cerner Multum,  Inc. "Australian Product Information." O 0</p><p id="ref_2">2. "Product Information. Fragmin (dalteparin)." Pharmacia and Upjohn, Kalamazoo, MI. </p><p id="ref_3">3. Cerner Multum,  Inc. "UK Summary of Product Characteristics." O 0</p><h2>More about Fragmin (dalteparin)</h2><ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy or 
Breastfeeding</li>
<li>Dosage Information</li>
<li>Drug Interactions</li>
<li>Compare Alternatives</li>
<li>Pricing &amp; Coupons</li>
<li>En Espa√±ol</li>
<li>1 Review</li>
<li>Drug class: heparins</li>
</ul><h3>Consumer resources</h3><ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>Fragmin &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
</ul><h3>Professional resources</h3><ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li data-more-config-id="list-data-resources-professional">... +1 more</li>
</ul><h3>Related treatment guides</h3><ul class="more-resources-list more-resources-list-conditions">
<li>Deep Vein Thrombosis Prophylaxis after Hip Replacement Surgery</li>
<li>Angina</li>
<li>Deep Vein Thrombosis Prophylaxis after Abdominal Surgery</li>
<li>Deep Vein Thrombosis Prophylaxis after Orthopedic Surgery</li>
<li data-more-config-id="list-data-resources-conditions">... +3 more</li>
</ul><h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p><p>Some side effects may not be reported. You may report them to the FDA.</p><p class="ddc-disclaimer-link">Medical Disclaimer</p>